NSE: SUPRIYA | BSE: 543434

Mid-range Performer

Download real time

783.95 -7.70 (-0.97%)

27.75% Fall from 52W High

97,607 NSE+BSE Volume

NSE 26 Aug, 2026 12:56 PM (IST)

6,309.4

Market Cap

Above industry Median

Beta 1Year

Very Low volatility

Supriya Lifescience Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for SUPRIYA, BSE:543434 Supriya Lifescience Ltd.

Search Inside the pdf :

Supriya Lifescience Ltd.

17 Aug 2026

783.95

-0.97%

Outlook

Accumulate: Supriya Lifescience Ltd.

Target

Deven Choksey

Supriya Lifescience’s growth remains backended to H2 FY27, with management reiterating its INR 1,000 crore revenue target and 33-35% EBITDA margin guidance as Q1 headwinds from solar policy charges and water shortages were temporary.

Supriya Lifescience Ltd. is trading below its 30 day SMA of 843.1

Supriya Lifescience Ltd.

09 Jun 2026

783.95

-0.97%

Product Diversification and Manufacturing Expansion Strengthen Growth Visibility

Accumulate: Supriya Lifescience Ltd.

Target

Deven Choksey

Supriya Lifescience is evolving from a niche anesthetic API player into a diversified specialty API company with multiple growth engines.

Deven Choksey decreased Accumulate price target of Supriya Lifescience Ltd. to 841.0 on 17 Aug, 2026.

Supriya Lifescience Ltd.

18 Nov 2025

783.95

-0.97%

Strong sequential rebound with broad-based growth; exports and Module E ramp-up drive performance

Accumulate: Supriya Lifescience Ltd.

Recommendation Target

Deven Choksey

We expect growth momentum to sustain over the coming quarters, supported by steady demand across regulated markets, scale-up of the Module E facility, and a stronger mix from high-value therapies.

Supriya Lifescience Ltd. is trading above its 200 day SMA of 755.9

Supriya Lifescience Ltd.

22 Aug 2025

783.95

-0.97%

Short-term weakness; robust pipeline supports outlook

Buy: Supriya Lifescience Ltd.

Deven Choksey

We have revised our FY26E/FY27E EPS estimates by -3.8%/+0.3% primarily to reflect miss in the Q1FY26 performance, and higher depreciation expenses, however, FY27 numbers are intact with rising regulated market share, enhanced backward integration, scale-up of the DSM contract, and new launches such as contrast media and ADHD APIs.

Supriya Lifescience .. has an average target of 841.00 from 1 broker.

Supriya Lifescience Ltd.

22 Dec 2023

783.95

-0.97%

Pick of the Day (Short Term Delivery Call)

Accumulate: Supriya Lifescience Ltd.

SBI Securities

SLL has a niche product basket of 38 APIs with presence in therapeutic areas of Analgesics, Anti-histamine, vitamins, anti-asthmatics, anti-allergic and anti-malarial. The company has tied up with
Kalinga Institute of Technology for development of GelHeal and Quickblue Oral Kit.

Supriya Lifescience Ltd. is trading below its 30 day SMA of 843.1

Supriya Lifescience Ltd.

16 Dec 2021

783.95

-0.97%

Supriya Lifescience : IPO

IPO Note: Supriya Lifescience Ltd.

ICICI Securities Limited

Supriya has been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, contributing to 45-50% and 60-65%, respectively, of the API exports from India, between FY17 and FY21. SLL is among the largest exporters of Salbutamol Sulphate in India contributing to...

Supriya Lifescience Ltd. is trading below its 30 day SMA of 843.1

Supriya Lifescience Ltd.

16 Dec 2021

783.95

-0.97%

SUPRIYA LIFESCIENCES LTD.

IPO Note: Supriya Lifescience Ltd.

Hem Securities

Supriya Lifescience is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (APIs), with a focus on research and development. As of October 31, 2021, company have niche product offerings of 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic,...

Deven Choksey decreased Accumulate price target of Supriya Lifescience Ltd. to 841.0 on 17 Aug, 2026.

Supriya Lifescience Ltd.

15 Dec 2021

783.95

-0.97%

Supriya Lifescience Ltd. IPO Note

IPO Note: Supriya Lifescience Ltd.

Ashika Research

Public issue of 2,55,47,445 Equity shares of Face value Total Public 2 each, (Comprising of fresh issue of 72,99,270 Equity Shares* (Rs. 200 cr.) and Offer for Sale of 1,82,48,175 Equity Shares* (Rs. 500 cr.) by Selling Shareholder)....

Supriya Lifescience Ltd. is trading above its 200 day SMA of 755.9

Supriya Lifescience Ltd.

15 Dec 2021

783.95

-0.97%